The third-generation ALK inhibitor lorlatinib overcomes crizotinib resistance in vivo in patient-derived xenografts harbouring F1174L or F1245C mutations [108,109], and is presently being investigated in high-risk neuroblastoma patients (clinical trial: NCT03126916) following promising early reports of anti-tumour activity and tolerability in a phase I clinical trial [110]. Here, ALK is linked to neoplasm.